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Primary dystonia (pD) is a movement disorder characterized by sustained or intermittent
muscle contractions causing abnormal, often repetitive, movements, postures, or both.
Gilles de la Tourette syndrome (GTS) is a childhood-onset neuropsychiatric developmen-
tal disorder characterized by motor and phonic tics, which could progress to behavioral
changes. GTS and obsessive–compulsive disorders are often seen in comorbidity, also sug-
gesting that a possible overlap in the pathophysiological bases of these two conditions.
PET techniques are of considerable value in detecting functional and molecular abnor-
malities in vivo, according to the adopted radioligands. For example, PET is the unique
technique that allows in vivo investigation of neurotransmitter systems, providing evidence
of changes in GTS or pD. For example, presynaptic and post-synaptic dopaminergic studies
with PET have shown alterations compatible with dysfunction or loss of D2-receptors bear-
ing neurons, increased synaptic dopamine levels, or both. Measures of cerebral glucose
metabolism with 18F-fluorodeoxyglucose PET (18F-FDG PET) are very sensitive in show-
ing brain functional alterations as well. 18F-FDG PET data have shown metabolic changes
within the cortico-striato-pallido-thalamo-cortical and cerebello-thalamo-cortical networks,
revealing possible involvement of brain circuits not limited to basal ganglia in pD and GTS.
The aim of this work is to overview PET consistent neuroimaging literature on pD and GTS
that has provided functional and molecular knowledge of the underlying neural dysfunc-
tion. Furthermore, we suggest potential applications of these techniques in monitoring
treatments.
Keywords: PET, primary dystonia, Tourette syndrome, movement disorders, neuroimaging, statistical parametric
mapping, treatment monitoring
INTRODUCTION
The dystonias are a heterogeneous group of hyperkinetic move-
ment disorders characterized by disabling spasms of the body
due to sustained or intermittent muscle contractions causing
abnormal, often repetitive, movements, postures, or both (1).
There has been a rationalization of the classification of dystonia
and a greater understanding of the causes of dystonic movements
from the study of genetics, neurophysiology, and functional imag-
ing in the most prevalent form of dystonia syndrome, primary
dystonia (pD) (2). Three basic parallel approaches are used to
classify pD: age of onset (early or late), distribution of affected
body parts (focal, segmental, or multifocal), and cause (presence
or absence of genetic factors) (2).
Gilles de la Tourette syndrome (GTS) is a childhood-onset
complex neurobehavioral disorder defined by motor and phonic
tics, which can be often complicated by comorbid conditions that
could progress to behavioral changes (3, 4). GTS and obsessive–
compulsive disorders (OCD) indeed are often seen in comorbidity,
also suggesting that a possible overlap in the pathophysiological
bases of these two conditions. The exact etiology of GTS remains
unknown, but the impairment of cortico-striatal-thalamo-cortical
(CSTC) network seems to be the primary site of underlying
damage.
PET molecular and functional neuroimaging techniques have
been used to investigate the neural basis of movement disorders,
as well as to identify potential cerebral targets for medical and
surgical therapies. These techniques have provided evidence for
specific alterations of both glucose metabolism and neurotrans-
mitter systems in movement disorders, also useful for differential
diagnosis (5). A very intriguing and promising application of 18F-
fluorodeoxyglucose PET (18F-FDG PET or perfusion 15O-H2O) is
the monitoring of the brain stimulation treatments in movement
disorders (i.e., deep brain stimulation – DBS), together with the
related assessment of the functional metabolic post-stimulation
changes. Also, statistical parametric mapping (SPM) procedures
allow robust voxel-based single-subject analysis (6) useful for
treatment monitoring. The chance to run voxel-based single-
subject analyses is of particular interest, given the low number
of patients usually undergoing surgical stimulation treatments. To
date, multiple reports have used similar approaches to define how
stimulation treatments exert their effects in various movement
disorders, like in pD (7, 8), and GTS with PET molecular imaging
(9). Since the clinical manifestations of these movement disorders
may be very heterogeneous and peculiar, PET monitoring could
play a supportive and crucial role in evaluating the effects of the
treatments and the progression of the diseases.
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Functional (fMRI) and structural magnetic resonance imaging
using advanced techniques as diffusion tensor imaging (DTI) have
also been applied to the study of brain functional mechanisms and
macrostructural abnormalities underlying movement disorders.
As for pD, in sporadic cases as well as in genetic mutation carriers,
DTI showed changes in the integrity of white matter fiber tracts
by means of indices like fractional anisotropy or mean diffusivity
(10). Similarly, DTI-based studies in GTS yielded clear evidence
of reduced microstructural integrity of white matter extending
beyond motor pathways. These studies suggest that alterations of
the connecting systems in these diseases, also with evidence for
anatomo-clinical correlations (11, 12).
Advances in PET medical technology imaging have helped to
further clarify the pathophysiology of specific movement disor-
ders, showing the associated metabolic and molecular alterations.
In pD, 18F-FDG PET revealed a consistent pattern of hypermetab-
olism, encompassing basal ganglia, and sensorimotor pathways (5,
13). In GTS, 18F-FDG PET provided evidence for hypermetabo-
lism occurring at sensorimotor cortex level and hypometabolism
in the limbic cortex and striatum (14). In addition, cerebral per-
fusion activation studies in GTS (by means of 15O-H2O and PET)
have also provided functional evidence for activations in the cere-
bellum, insula, thalamus, and putamen during tic release. This
prominent involvement of cerebellum and insula, suggested that
their recruitment in tic initiation and execution (15).
In addition, PET molecular imaging, with specific radiotracers,
such as [11C]raclopride, alpha-[11C]methyl-l-tryptophan (11C-
AMT), 11C-flumazenil, 11C-WIN (DA transporter antagonist),
11C-MCN (a 5-HT2A-R antagonist), and 11C-MDL (a SERotonine
Transporter – SERT – antagonist) have represented a unique tool
for in vivo evaluation of the biochemical mechanisms underlying
motor dysfunctions. Studies of the neurotransmitters pathophys-
iology revealed multiple and complex underlying biochemical
disorders.
All above supports the crucial role of PET investigations in
better identifying the underlying pathophysiological mechanisms
of pD and GTS disorders, showing also a potential application
in treatment monitoring. The main advantage of such tech-
niques is the possibility to in vivo investigate the changes in
brain metabolism and neurotransmission systems before and after
treatment.
This brief overview addresses the functional alterations in the
networks and the interactions with neurotransmission systems in
pD and GTS. It also discusses the innovative use of PET molecular
imaging as a tool for monitoring interventional therapy and its use
as an outcome measure.
PRIMARY DYSTONIA
CLINICAL CHARACTERIZATION
Primary dystonia typically begins in late childhood or adolescence
and it is traditionally attributed to basal ganglia dysfunction (16).
It is of note that no specific pathological lesions of these structures
have been consistently evidenced in post-mortem studies (17). pD
is defined as a movement disorder characterized by sustained or
intermittent muscle contractions causing abnormal, often repeti-
tive, movements, postures, or both (1). Dystonic movements are
typically patterned and twisting, and may be tremulous too. These
movements are often primed or worsened by voluntary actions and
associated with overflowing muscle activation. pD can be classi-
fied along two axes, as defined by Albanese et al. (18): (1) clinical
characteristics including age at onset, body distribution, temporal
pattern, and associated features (additional movement disorders
or neurological features); and (2) etiology and inheritance. The
clinical characteristics fall into several specific dystonia syndromes
that might help in a better diagnosis and strategic treatment. In
regards to genetic forms, DYT1 and DYT6 are the most common
and are inherited as autosomal dominant traits with incomplete
penetrance (19–21).
18F-FDG PET EVIDENCE
Several 18F-FDG PET neuroimaging studies have provided knowl-
edge on the functional anatomy of pD. Lehericy et al. (22,
23), in their comprehensive reviews on neuroimaging of dysto-
nia using fMRI and 18F-FDG PET, highlighted the hyperactivity
of premotor and prefrontal areas and the hypoactivity of pri-
mary sensorimotor areas. Thus, since regions other than the
basal ganglia are involved in dystonic movements, neuroimag-
ing evidence supports the hypothesis of pD as a circuit dis-
order. Coherently, most of the literature converges in support-
ing the involvement of both basal ganglia-thalamo-cortical and
cerebello-thalamo-cortical pathways (19, 23, 24).
More specifically, 18F-FDG PET has been used in different
dystonic disorders including primary generalized dystonia and
DOPA-responsive dystonia (DRD), as well as in focal dystonic
syndromes such as spasmodic torticollis, writer’s cramp, and ble-
pharospasm (25–27). Common findings concern functional meta-
bolic abnormalities in the basal ganglia and associated outflow
pathways to sensorimotor cortex and to other regions involved
with motor control (5). Hutchinson et al. studied the brain
metabolic pattern in six subjects with essential blepharospasm
compared to normal volunteers. They showed that the clinical
manifestations were associated with abnormal metabolic activity
in the pons and cerebellum, and with additional abnormalities also
in cortical eyelid control regions (27).
Asanuma et al. (10), by studying subjects’ torsion dystonia-
related pattern, showed a relative increase in the metabolic activity
of the posterior putamen, globus pallidus (GP), cerebellum, and
supplementary motor area (SMA).
All these results contribute to consider pD as a neurocircuit dis-
order, involving the cortico-striato-pallido-thalamo-cortical and
cerebello-thalamo-cortical pathways, which are recognized as a
cause of the clinical manifestations (28, 29). An aberrant motor
response is thought to result from abnormal processing at a level of
central sensorimotor integration and as a disturbance of sensory
input at the level of spinal interneuronal circuits (23).
18F-fluorodeoxyglucose PET imaging applied to manifesting
and clinically non-manifesting gene carriers has offered the pos-
sibility of identifying alterations in circuit functional connectivity
associated with both genotype and penetrance. For example, in
regards to torsion dystonia, some authors hypothesized that its
related metabolic pattern (TDRP, hypermetabolic at putamen, pal-
lidus, SMA, and cerebellum levels) can potentially be used as a
marker in linkage studies to identify potential gene carriers among
family members of pD patients (28). Similarly, in patients with
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pD due to DYT1 mutation, an abnormal metabolic brain net-
works was reported,characterized by hypermetabolism in the basal
ganglia, SMA, and cerebellum (10). Trost et al. have quantified
the metabolic activity of this network in patients carrying differ-
ent pD mutations, in order to investigate whether this functional
abnormality is linked to genotype. Their findings suggest that a
consistent abnormal metabolic topography that is not genotype
specific, being present in carriers of other pD mutations (30).
Recently, Carbon et al. (31) identified that brain regions with
metabolic changes in DYT11 myoclonus-dystonia (DYT11-MD)
showed specific patterns of metabolic abnormalities, involving
connecting pathways between the cortex, basal ganglia, thalamus,
and cerebellum. In addition, they compared metabolic abnormal-
ities in DYT11-MD with those found in other forms of hereditary
dystonia and in post-hypoxic myoclonus. They found significant
DYT11 genotype-specific metabolic increases in the inferior pons
and in the posterior thalamus as well as reductions in the ventro-
medial prefrontal cortex. Significant phenotype-related increases
were also present in the parasagittal cerebellum. This latter abnor-
mality was shared with post-hypoxic myoclonus, but not with
other forms of pD. These findings were consistent with the hypoth-
esis of a sub-cortical myoclonus generator presence in DYT11-MD,
particularly likely to involve the cerebellum (31). This evidence
shows how 18F-FDG PET imaging can help identify different
abnormal metabolic networks in specific variants of movement
disorders such as in the context of pD.
PET NEUROTRANSMISSION STUDIES
Primary dystonia is a very complex disease spectrum, in which
a pathological phenomena elicits a cascade of events encompass-
ing different networks and molecular systems, from dopamine to
GABA (32, 33) and also, as recently shown, acetylcholine (ACh)
(34). In pD, PET and appropriate radiotracers have been used, in
particular, for the assessment of dopaminergic system to investi-
gate whether alterations in striatal receptor binding are showed
by patients. Historically (1997), landmark evidence showed alter-
ations of D2-R binding in putamen in focal dystonias, as measured
by 18F-spiperone (reduced by up to 29%) (35). More recently,
the adoption of 11C-raclopride (a very specific radioligand for
D2-R) yielded consistent results across various studies in dif-
ferent forms of pD. Künig et al. (36) evaluated in 14 patients
with DRD, the dopamine D2-R binding by 11C-raclopride PET
in comparison with 16 levodopa-treated Parkinson’s disease (PD)
patients and 26 healthy controls (HCs). The DRD patients showed
increased 11C-raclopride binding in the putamen and caudate
nucleus when compared with both controls and PD patients.
The results were interpreted as reflecting reduced tracer dis-
placement by endogenous dopamine, or as an alteration of the
receptor’s features due to chronic dopamine deficiency. In addi-
tion, the differences in 11C-raclopride binding between DRD and
PD patients in the caudate nucleus, suggest that this structure
may be of pathophysiological relevance in the presentation of the
clinical features of both diseases (36). Coherently, Rinne and co-
workers investigated the integrity of striatal dopaminergic system
in seven patients with DRD using PET with different radiotracers
to evaluate dopamine transporter functioning (DAT ligand 11C-
CFT), D1 (11C-NNC756), and D2-R (11C-raclopride). The results
showed increased striatal dopamine D2-R availability in DRD with
unchanged dopamine D1 receptors and DAT ligand binding. The
increased D2-R availability seems to be due to reduced compe-
tition by endogenous dopamine or a compensatory response to
dopamine deficiency, or both (37). 11C-raclopride has been also
recently used to investigate another focal dystonia, namely, writer’s
cramp (38). Berman et al. analyzed striatal D2/D3 availability at
rest and during endogenous dopamine release during sequential
finger tapping and speech production tasks in 15 patients with
writer’s cramp and 15 matched HC subjects. This work showed
that patients with writer’s cramp may have divergent patterns of
striatal dopamine release during both a motor task (involving the
dystonic hand) and an unrelated asymptomatic task, like sentence
production (38). On the other hand, 11C-raclopride PET showed
its efficacy also in investigating commonalities and divergences
between different forms of genetic mutation dystonia, like DYT1
and DYT6 (33, 39).
Asanuma et al. (39) studying the DYT1 mutation with 11C-
raclopride, found a 15% reduction of tracer binding in caudate and
putamen in subjects without clinical manifestations. While this
could have been interpreted as a trait feature of DYT1 mutation,
later works with the same radiotracer showed similar reductions
a in DYT6 mutation as well (33). These changes, which may be
present in different degrees in the DYT1 and DYT6 genotypes,
are likely to represent susceptibility factors for the development of
clinical manifestations in mutation carriers (33). It is of note that
a recent study revealed unaltered D1 receptor binding (by means
of 11C-NNC112 PET) in primary focal dystonias when compared
with HCs (40).
This suggests that dopaminergic post-synaptic alteration may
be an early pathological trait of the condition, not sufficient per se
in eliciting the full clinical phenotype (5).
Since preclinical and indirect clinical evidence suggest that
molecular changes also of the GABAergic control system might
represent a key dysfunctional component leading to disinhibi-
tion of the sensorimotor system (41, 42). Garibotto et al. used
11C-flumazenil PET in patients with sporadic and DYT1 muta-
tion pD in order to assess the integrity of the GABAergic system.
The results revealed a reduction in GABAA receptor expression or
affinity, both in DYT1 carriers and sporadic patients in primary
motor and premotor cortex, primary and secondary somatosen-
sory cortex, and in the motor component of the cingulate gyrus.
Clearly, a deficit in GABAergic function might indeed result in
abnormalities of neuronal inhibition affecting both the motor and
somatosensory systems. In particular, the reduced inhibitory con-
trol in somatosensory cortices might suggest that the GABA system
plays a crucial role in the modulation of the afferent signal to the
somatosensory cortex in pD (43). Noteworthy, a MR spectroscopy
study in patients with pD, revealed a significant decrease in GABA
levels in the sensorimotor cortex and lentiform nuclei contralateral
to the affected side, thus, providing indirect evidence supporting
the relevant role of this system in pD (44).
As claimed by Tanabe and co-workers, even-though anti-
cholinergic medications are effective in DYT1 and other forms
of dystonia, this does not necessarily imply a primary role of ACh
in these disorders. In point of fact, the abnormal cholinergic func-
tioning may result as a secondary effect of the altered dopaminergic
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neurotransmission in the striatum (34) and this imbalance may
have a role in symptom generation, as showed recently in DYT1
animal models (45).
GILLES de la TOURETTE SYNDROME
CLINICAL CHARACTERIZATION
Gilles de la Tourette syndrome is a childhood-onset neuropsychi-
atric developmental disorder characterized by motor and phonic
tics that are defined as involuntary or semivoluntary, sudden,
intermittent, repetitive movements (motor tics), or vocalizations
(phonic tics) (3). Comorbidities are very common, in particular,
OCD and attention deficit hyperactivity disorder (46). It is of note
that the exact etiology of GTS remains unknown. Volumetric MRI
in GTS provided evidence for correlations between tic severities
and volume of specific structures [e.g., caudate, see Ref. (47)] and
also for abnormal gray matter volumes in prefrontal cortex in
children and adults [see Ref. (48, 49), and for review see Ref. (50,
51)]. Functional neuroimaging techniques, such as single-photon
emission computed tomography (SPECT), PET, and fMRI have
provided some evidence for the underlying pathological mecha-
nisms in GTS that enabled new hypotheses on its pathophysiology
to be formulated (50, 51). In particular, these studies suggest that
the involvement of the CSTC network in the pathophysiology of
tics and associated psychopathological manifestations in GTS (19).
18F-FDG PET EVIDENCE
18F-fluorodeoxyglucose PET investigations, also through ad hoc
parametric measurements and/or voxel-wise statistical analysis,
have shown that regions other than the basal ganglia circuits may
be involved in GTS [see for example Ref. (14, 52)]. It has been
hypothesized that abnormal connections between basal ganglia,
thalamus, and cortex (within the CSTC circuitry) may be specifi-
cally associated to this condition (53). GTS has been significantly
characterized by (a) lower metabolic rates in caudate nucleus and
thalamus, (b) possible association with hypoactivity in lentiform
nuclei and hippocampal formation, and (c) higher metabolic rates
in the sensorimotor cortices (14, 15, 54, 55).
Pourfar et al. showed resting-state reduced metabolic activity
in the striatum and orbitofrontal cortex, and it was associated with
relative metabolic increases in premotor cortex and in cerebellum
in GTS-related metabolic pattern. Further analysis of the same
cohort, revealed that OCD symptoms in GTS patients were related
with a second metabolic pattern, characterized by (a) reduced
metabolic activity in the anterior cingulate and dorsolateral pre-
frontal cortices and (b) associated increases in primary motor
cortices and precuneus. The authors conclude that the different
clinical manifestations of GTS are associated with the expression
of these two distinct abnormal metabolic brain networks (14).
Correlation analysis between glucose metabolism and clini-
cal evidence contributed in characterizing the system networks
affected in this neuropsychiatric disease, which might be useful in
correct identification of the disorder. 18F-FDG PET studies have
shown significant correlations between the presence of tics and
hypermetabolism in several brain regions, including the medium
and lateral premotor cortices; the primary motor cortices; the
inferior parietal cortices; as well as the anterior cingulate cor-
tex, putamen, and caudate and Broca’s area (53). These results
support hyperactivity of the systems involved in motor plan-
ning/structuring and in the processing of sensory inputs at the
basis of GTS symptoms. In summary, GTS shows heterogeneity
of cortical and sub-cortical metabolic alterations depending on
different factors not yet completely identified, thus, hindering the
characterization of a specific metabolic pattern. Nonetheless, 18F-
FDG PET at single-subject level represents a useful tool for the
assessment of brain functional deficits, giving the chance to mon-
itor personalized brain target therapy and to assess the efficacy of
treatments.
PET NEUROTRANSMISSION STUDIES
Few PET molecular studies of neurotransmission systems pro-
vided insights on the underlying pathophysiology of GTS. Histor-
ically, GTS has always been linked to a dysregulation of dopamine
neurotransmission system (52, 56), also given the evidence for
reductions of TIC severity in treatments with D2-R antagonists
(57). Coherently, early post-mortem studies also provided evi-
dence for alterations in second messenger system (58) and also
for a possible relation between clinical phenotypes of GTS and
dopamine innervation in the striatum (3H-mazindol showed an
increased density of uptake sites) (59). To date, other neurotrans-
mission systems like serotonin or GABA have been investigated in
GTS (15, 60, 61).
Singer et al. tested the presynaptic dopamine release from
the striatum after amphetamine administration in GTS adult
patients using 11C-raclopride PET. Results were consistent with
the possibility that the pathologic mechanisms in GTS relate to an
abnormal regulation of the phasic dopamine response, resulting
in hyper responsive spike-dependent dopaminergic system activa-
tion. Thus, a tonic/phasic imbalance in the DA system may help to
explain the DA pathophysiology associated with GTS that could
be crucial in developing potential pharmacologic treatments (62).
Behen et al. used 11C-AMT PET to assess global and focal brain
abnormalities of tryptophan metabolism and their relationship
to behavioral phenotype in children with GTS and healthy age-
matched controls. Their results show cortical and sub-cortical
abnormalities of tryptophan metabolism in GTS, in particular,
in the dorsolateral prefrontal cortex (DLPFC) and bilateral thal-
amus levels, providing a strong neuroimaging evidence for a role
of serotoninergic mechanisms in the pathophysiology of GTS
(60). Saporta et al. (61), using 11C-AMT PET and DTI investi-
gated both structural white matter abnormalities and serotonin
synthesis in children with GTS. The authors hypothesized that
microstructural alterations and related altered connectivity in
CSTC might have been the primary abnormality in GTS, then
inducing altered neurotransmission. They found an asymmetric
immature microstructure in the caudate nucleus that was associ-
ated with abnormally increased serotonin synthesis. The authors
suggest that the increased serotonin synthesis in the caudate could
be due to cortical disinhibition, in the context of abnormal cortico-
striatal connectivity. On this basis the authors suggest serotonin
system as a possible new therapeutic target in GTS (61). Interest-
ingly, Lerner et al. (63), in the first study of GABA neurotrans-
mission system in GTS patients using 11C-Flumazenil and PET
found a consistent decrease of GABAa receptors in multiple lim-
bic regions such as amygdala, ventral striatum, thalamus, and also
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at the insula level. An increase of these receptors was also present
in the cerebellum, in the bilateral substantia nigra (SN) at peri-
aqueductal gray (PEG) level and in the right posterior cingulate
cortex (63).
In addition, besides the evaluation of isolated systems, insights
on underlying GTS pathophysiology have been provided by stud-
ies on neurotransmitters inter-modulation. Wong et al. (64)
studied both dopaminergic and serotoninergic neurotransmitter
systems at transporter and at receptor density levels, as mea-
sured by, respectively, 11C-raclopride and 11C-WIN (Dopamine
Active Transporter – DAT antagonist) or 11C-McN (5-HT2aR
antagonist) and 11C-MDL (SERT antagonist). In particular, they
tested whether there was a connection between phasic DA release
(DAREL) induced by administration of amphetamine and lev-
els of 5-HT in patients with GTS plus OCD comorbidity. They
found a strong correlation between DAREL and low levels of 5-HT,
suggesting that “DAREL is a primary defect in GTS” (64).
Further investigations in larger patient groups are neces-
sary in order to further elucidate the complex neuromodulation
changes in GTS.
PET NEUROIMAGING AND STIMULATION TREATMENT
MONITORING: EVIDENCE IN pD AND GTS
As anticipated in the introduction, a promising approach is to
use PET techniques (mainly perfusion 15O-H2O and/or 18F-FDG
PET) to monitor therapy efficacy in a variety of conditions and
across different type of medical and surgical treatments. For
example, PET techniques have shown a high value in monitor-
ing the effects of surgical therapies like DBS, which has been
extensively adopted in movement disorders (65). Clinically, recent
studies assessing the efficacy of stimulating treatments as DBS
or repetitive transcranial magnetic stimulation (rTMS) at specific
movement-related regions (such as globus pallidum or premotor
cortices) have demonstrated some positive effects in attenuating
the symptoms (66–69).
PET with perfusion radiotracers for monitoring treatments in
pD and GTS is not routinely used in clinical practice but some
authors, even if with a small cohort of patients, have demon-
strated the feasibility and the potential role of this approach in
specific setting of post-therapy assessment (see Table 1 for dys-
tonia). Kumar and colleagues (70) studied the effects of bilateral
GP DBS, by means of clinical assessment and of 15O-H2O PET,
in a case of medication-refractory generalized dystonia, taking
into account different stimulators settings and induced motor
conditions. The authors found a positive clinical improvement
after 1 year of DBS, also during active condition in terms of reac-
tion times and randomness of movements, “due to suppression
of dystonic patterned involuntary movements.” Coherently, PET
investigation showed that bilateral GP DBS, during the action
(moving a joystick), was reducing activity in lentiform nuclei,
motor areas (primary, premotor, SMA), and also in control areas
such anterior cingulate or prefrontal cortices (70). Detante et al.
(7) studied the effects of internal DBS on bilateral GP by assess-
ing regional cerebral blood flow (by means of 15O-H2O and PET)
in a sample of six patients with primary generalized dystonia.
Authors designed two test conditions, namely, OFF (no stimu-
lation) and ON (unilateral DBS GPi stimulation). During OFF
Table 1 |Table showing papers in literature (chronological order)
adopting PET for effects assessment of stimulation treatment in
dystonia.
Reference Dystonia Sample Stimulation Region Tracer
type
(70) gD Case study DBS bilGP 15O-H2O
(7) pgD 6 DBS bilGPi 15O-H2O
(72) pfD Case study DBS+epidural
cortical
stimulation
GPi+
pMC
18F-FDG
(71) tD 5 DBS GPi 15O-H2O
(8) pfD 7 Epidural
cortical
stimulation
preMC 18F-FDG
gD, generalized dystonia; pgD, primary generalized dystonia; pfD, primary focal
dystonia; tD, tardive dystonia.
condition, PET data showed overactivity in DLPFC, medial and
superior frontal gyrus (medFG/supFG), OFC, and thalamus. Dur-
ing ON condition, while stimulation was being administered to
the contralateral side of the most dystonic hand (assessed during
OFF condition), PET data showed a decrease of the overactivity
in the same areas and also in the putamen (7). Finally, Thobois
et al. studied the effects of DBS with 15O-H2O PET in GPi in
five patients with tardive dystonia (induced by neuroleptics). Dif-
ferences in brain perfusion induced by GPi stimulation between
motor execution and rest condition confirm that the increased
activity of prefrontal cortex and premotor areas can be modulated
with DBS (71). Besides 15O-H2O PET, also 18F-FDG PET has been
used in monitoring stimulation treatments (8, 72), showing a very
high accuracy and reliability.
Notably, the potential of 18F-FDG PET in detecting regional
glucose metabolism abnormalities can be improved using voxel-
based statistical methods (such as SPM). This parametric approach
has been applied in pD to evaluate, at a voxel-level, brain glu-
cose metabolism changes before and after brain stimulation (8,
72). For example, Lalli et al. (8) have assessed the efficacy and
safety of epidural premotor stimulation in patients with pri-
mary focal dystonia using 18F-FDG PET and SPM8 for statistical
voxel-based analysis (VBA). In order to define regional cerebral
metabolism differences, patients were compared to HCs at pre-
surgery and post-surgery conditions. The authors found that the
sensorimotor cortex was specifically involved in focal dystonia,
with hypermetabolism (relatively to HCs) at baseline and a reduc-
tion of hyperactivity after epidural stimulation, suggesting that
a positive effect of brain stimulation (Figure 1). These findings
confirmed the notable role of PET to elucidate the underlying
metabolic mechanisms, together with the chance to track and
monitor treatments progression (8). Some years before, Romito
et al. (72) used, in a case of primary fixed dystonia, 18F-FDG PET
and SPM99 to monitor the effects of an epidural motor cortex
stimulation treatment that significantly reduced the severe dys-
tonic symptoms. This patient experienced null benefits during
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FIGURE 1 | Patients with epidural premotor cortical stimulation in primary focal dystonia. Results of SPM8 group analysis showing increased metabolism
in the patient group at (A) pre-surgery and (B) post-surgery conditions compared to normal controls. Modified from Ref. (8).
internal GP (GPi) stimulation, which is commonly effective in
these conditions. Therefore, the authors decided to apply cor-
tical motor areas stimulation that in 6 months, elicited notable
improvements in fixed dystonia and in movements. In this study,
18F-FDG PET was then used to characterize the metabolic changes
induced by the different treatments, revealing that GPi stimu-
lation was inducing an increase of glucose metabolism in the
sensorimotor cortex (L>R), SMA, and anterior cingulate gyri
bilaterally. Conversely, motor cortex stimulation was inducing
a reduction of glucose metabolism in the bilateral cerebellum.
Despite the few earlier reports in literature, the author concluded
that motor cortex stimulation may be an effective treatment in
focal dystonia (72).
In the previous paragraphs, we have discussed how PET imag-
ing can be useful in characterizing metabolic and neurotransmis-
sion abnormalities in GTS, suggesting that its potential application
in treatment monitoring in these patients. Notwithstanding, only
few reports are currently available in the literature of therapy
assessment in GTS. Hopefully, future studies will further apply
these techniques, given the urgency of defining effective treatments
and provide appropriate safe care. Besides 15O-H2O and18F-FDG,
PET molecular imaging may be useful too, given all the evidence
of multiple neurotransmitters systems alteration in GTS.
For example, Vernaleken et al. studied, in a case study, the effect
of thalamic DBS in a GTS patient by means of 18F-Fallypride PET
(73). The aim of the authors was to clarify the mechanisms of
DBS-induced modulatory effects on GTS symptoms in vivo. They
found that this stimulation treatment exerted its effects through
the modulation of the dopaminergic neurotransmission system.
Given the success of this pilot study, some years later, the same
group further investigated the dopamine modulation (still with
18F-Fallypride PET) induced by DBS in three GTS patients (9). The
authors, evaluating the results, took into account all the possible
confounding factors (from anesthesia for the long-PET scan dura-
tion to low-subjects number) concluding that DBS may exert its
effects modulating the hyperactive dopamine transmission within
the basal ganglia circuitry (9).
CONCLUSION: SUMMARY AND FUTURE DIRECTIONS
The most applied PET neuroimaging approaches in movement
disorders include functional and molecular imaging using 18F-
FDG PET and neurotransmitter-specific tracers. Several studies
using PET techniques, also through ad hoc parametric measure-
ments or voxel-based statistical analysis (SPM) at both single-
subject and group-level, have shown that regions other than the
basal ganglia circuits are involved in pD and GTS. This can be
used to pinpoint a breakdown of organized trans-synaptic activ-
ity, which might distinguish these disorders. Indeed, in GTS and
pD, the CSTC circuit seems to play an important role in the
generation of tics and dystonia. Nevertheless, the precise local-
ization and mechanisms of these abnormalities remain disputed
and are a topic of active debate and research. Finally, despite some
authors have proposed the possible value of PET investigations for
early and differential diagnosis of movement disorders, further
researches and added knowledge on the distinct pathophysiolog-
ical basis are still necessary. Despite the doubtless value of PET
molecular techniques, it should always be taken into account
that these results might be undermined by confounding vari-
ables, such as age at onset, comorbidities, or ongoing medical
treatments.
PET studies involving larger clinical samples to investigate glu-
cose metabolic changes and integrity of neurotransmitter systems
(e.g., dopamine system with D2-R availability, DAT functioning
and amphetamine-induced DAREL) and controlling for confound-
ing variables, will surely provide further insights, particularly in
the measurement of the pathophysiological abnormalities. The
more these factors are evaluated and controlled, the greater the
value of the results will be, especially for clinical practice.
In regards to the assessment of therapeutic effects of DBS or
cortical stimulations by PET functional neuroimaging, it appears
very promising and offers a wide variety of applications. PET
techniques can be very useful in correctly identifying potential
targets for medical and surgical therapies. These tools can clearly
help in defining how the stimulations elicit their effects on the
brain functioning, both at treatment site and at whole-brain
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circuitry level. Evaluating therapy-induced changes in metabo-
lism or in neurotransmitters systems can be very challenging and
heavily dependent on raters’expertise. Semi-quantitative paramet-
ric approaches provide very informative data that is less affected
by inter-individual observer differences. These voxel-based analy-
ses, especially at single-subject level, have shown high accuracy in
monitoring stimulation treatment effects (6, 8, 72). We strongly
claim that the adoption of PET molecular and functional imag-
ing, especially with optimized parametric approaches, is of utmost
importance for monitoring of both medical and surgical therapies
in pD and GTS. Future further studies in this direction are wel-
come, in order to evaluate the potential of this methodology in
clinical practice.
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